Psoriatic arthritis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• IL-17 4
• TNF 4
• IL-23 0
• JAK 1
• GLP-1 3
• TYK2 0
• IL-1 0
• SGLT2 0
• GIP 1
• APOE 0
• BRCA2 0
• CD19 0
• FGFR 0
• G6PD 0
• IL-13 0
• NLRP3 0
• NRF2 0
• PDE4 0
• STAT3 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 692 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis

  NCT06431750· Novartis Pharmaceuticals· Updated 7 Aug 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

  NCT06522035· Enlivex Therapeutics Ltd.· Updated 13 Apr 2026

  “reprioritization”Registry text, quoted unchanged. Source

• Withdrawn

  Pregnancy and Medically Assisted Conception in Rare Diseases

  NCT02450396· Assistance Publique - Hôpitaux de Paris· Updated 27 Mar 2026

  “Abandonment of the study project”Registry text, quoted unchanged. Source

• Withdrawn

  Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy

  NCT07255781· University of California, San Diego· Updated 23 Feb 2026

  “The sponsor determined that enrollment would not meet their expectations and decided to withdraw the study.”Registry text, quoted unchanged. Source

• Terminated

  Psoriatic Arthritis Study of Izokibep

  NCT05623345· ACELYRIN Inc.· Updated 23 May 2025

  “Per our 13Aug24 press release, we announced discontinuation of internal development in this indication. This decision was not due to safety reasons.”Registry text, quoted unchanged. Source

• Terminated

  Quantitative Ultrasound of the Enthesis in Fibromyalgia and Psoriatic Arthritis

  NCT05447741· Centre hospitalier de l'Université de Montréal (CHUM)· Updated 25 Feb 2025

  “The recruitment and examination of participants were halted prematurely due to depleted funds.”Registry text, quoted unchanged. Source

• Terminated

  VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

  NCT05715125· Ventyx Biosciences, Inc· Updated 27 Dec 2024

  “sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil

  NCT06715254· Novartis Pharmaceuticals· Updated 4 Dec 2024

  “Due to the limited availability of eligible patients who met the study's criteria, as well as there has not been a case of tuberculosis, the study was terminated early.”Registry text, quoted unchanged. Source

• Terminated

  Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

  NCT05511519· Aclaris Therapeutics, Inc.· Updated 27 Nov 2024

  “Sponsor decision”Registry text, quoted unchanged. Source

• Withdrawn

  Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

  NCT05499416· Innovaderm Research Inc.· Updated 15 Mar 2023

  “Sponsor decision.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)

  NCT07923773· Novartis Pharmaceuticals· Source

• Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial

  NCT07111494· Medical College of Wisconsin· Source

• A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

  NCT05767047· Amgen· Source

• A Study of Guselkumab in Participants With Active Psoriatic Arthritis

  NCT04882098· Janssen Research & Development, LLC· Source

• A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

  NCT03773965· Eli Lilly and Company· Source

• A Long-term Extension Study of Ustekinumab in Pediatric Participants

  NCT05092269· Janssen Research & Development, LLC· Source

• A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

  NCT07321873· Janssen Research & Development, LLC· Source

• A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically

  NCT07654751· Janssen Research & Development, LLC· Source

• A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

  NCT04929210· Janssen Research & Development, LLC· Source

• A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants

  NCT07532226· Janssen-Cilag Ltd.· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Mendelian Randomization Analysis 6
• Gene Expression Profiling 9
• Exome Sequencing 1
• Proteomics 8
• Metabolomics 3
• Flow Cytometry 2
• Magnetic Resonance Imaging 23
• Machine Learning 8
• Cohort Studies 22
• Genome-Wide Association Study 9

• Psoriatic arthritis digital phenotyping and inflammation drivers (PDPID) study: protocol for an international multicentre prospective cohort.

  BMJ Open, Sept 2026

• Integrative Network Toxicology, Machine Learning, Single-Cell Analysis, scTenifoldKnk-Based Virtual Knockout, and Molecular Docking Suggest a Potential Molecular Link Between Aspartame and Rheumatoid Arthritis Involving HLA-DRB1.

  Int J Mol Sci, Jun 2026

• Clinical investigation of a digital biomarker for joint swelling in inflammatory arthritis based on automated quantification of dorsal finger fold patterns.

  Sci Rep, Jun 2026

• Using causal machine learning and real world data to improve dose response decision making for secukinumab in psoriatic arthritis.

  Sci Rep, Apr 2026

• Integrative bioinformatics-machine learning-experimental validation identifies shared immunomodulatory targets in psoriasis and psoriatic arthritis and deciphers allicin's therapeutic mechanism.

  Naunyn Schmiedebergs Arch Pharmacol, Dec 2025

• Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials.

  Arthritis Res Ther, Nov 2025

• Discrimination of Rheumatoid and Psoriatic Arthritis Based on Raman and NIR Spectra Using Machine-Learning Algorithms.

  Molecules, Nov 2025

• Explainable machine learning-based prediction of psoriatic arthritis flares using heterogenous real-world data for personalised patient care.

  Methods, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.